Single-isocenter volumetric-modulated Dynamic WaveArc therapy for two brain metastases.
Single-isocenter volumetric-modulated Dynamic WaveArc therapy for two brain metastases.
复制标题
针对两个脑转移瘤的单等中心体积调制 Dynamic WaveArc 疗法。
DOI：
10.1007/s11604-019-00849-9
复制
发表时间：
2019
期刊：
影响因子：
--
通讯作者：
Mizowaki T.
中科院分区：
文献类型：
--
作者：
Uto M;Ogura K;Mukumoto N;Miyabe Y;Nakamura M;Hirashima H;Katagiri T;Takehana K;Hiraoka M;Mizowaki T.
目的一种新的放射治疗技术--体积调制动态波弧疗法(VMDWAT)可以使用Vero4DRT进行，该疗法基于连续的非共面轨迹。本计划研究比较了多条直线非共面弧形的单等中心调容弧疗(VMAT)和单等中心VMDWAT治疗两种脑转移瘤患者的剂量分布和治疗时间。VMAT和VMDWAT计划都是使用单一等中心和28 Gy五次照射的处方剂量创建的。结果与VMAT相比，VMDWAT明显改善了mRTOG-CI和MIP-CI，减少了正常脑组织的体积。这两种方式在接受5、10、12、15和20Gy射线照射的正常脑组织体积方面没有显著差异。VMDWAT组平均治疗时间明显缩短。结论在两例脑转移瘤患者中，VMDWAT较VMAT在更短的治疗时间内显著改善了剂量分布。因此，单中心VMDWAT可能是两个脑转移瘤的一种有前途的治疗方法。
PurposeA new irradiation technique, volumetric-modulated Dynamic WaveArc therapy (VMDWAT), based on sequential non-coplanar trajectories, can be performed using the Vero4DRT. This planning study compared the dose distribution and treatment time between single-isocenter volumetric-modulated arc therapy (VMAT) with multiple straight non-coplanar arcs and single-isocenter VMDWAT in patients with two brain metastases.Materials and methodsTwenty patients with two planning target volumes exceeding 2.0 cm3were included. Both VMAT and VMDWAT plans were created with single isocenter and a prescribed dose of 28 Gy delivered in five fractions. Target conformity was evaluated using indices modified from the RTOG-CI (mRTOG-CI) and IP-CI (mIP-CI).ResultsVMDWAT significantly improved both mRTOG-CI and mIP-CI and reduced the volume of normal brain tissue receiving 25 and 28 Gy compared to VMAT. The two modalities did not significantly differ in terms of the volume of normal brain tissue receiving 5, 10, 12, 15, and 20 Gy. The mean treatment time was significantly shorter in the VMDWAT group.ConclusionVMDWAT significantly improved dose distribution in a shorter treatment time compared to VMAT in patients treated for two brain metastases. Single-isocenter VMDWAT may thus be a promising treatment for two brain metastases.